#1 Clinical Trials Search in Europe

Cldn6 Car-T

In the realm of cancer treatment, a groundbreaking clinical trial is underway to evaluate the safety and effectiveness of CLDN6 CAR-T, an innovative cell therapy. This study focuses on patients with advanced solid tumors that express the CLDN6 protein. The trial also investigates the potential benefits of combining CLDN6 CAR-T with a novel RNA-based vaccine. This article delves into the key aspects of this cutting-edge research, offering hope for patients with limited treatment options.

Table of Contents

What is CLDN6 CAR-T?

CLDN6 CAR-T is an innovative cell therapy being developed for the treatment of advanced solid tumors[1]. This therapy is also known by its product name BNT211 and is classified as an advanced therapy medicinal product[1]. CLDN6 CAR-T is a type of chimeric antigen receptor T-cell therapy, which involves modifying a patient’s own immune cells to target and fight cancer.

How Does CLDN6 CAR-T Work?

CLDN6 CAR-T therapy works by targeting a specific protein called claudin 6 (CLDN6) that is found on the surface of certain cancer cells[1]. The process involves:

  1. Collecting T-cells (a type of immune cell) from the patient’s blood
  2. Modifying these T-cells in a laboratory to express a special receptor that recognizes CLDN6
  3. Multiplying these modified T-cells
  4. Infusing the modified T-cells back into the patient’s body

Once infused, these modified T-cells can recognize and attack cancer cells that express CLDN6 on their surface.

Target Conditions

CLDN6 CAR-T is being investigated for the treatment of several types of advanced solid tumors, including[1]:

  • Malignant solid tumors: These are cancers that form solid masses in various organs of the body
  • Carcinoma of unknown primary: A type of cancer where the original site of the tumor is not known
  • Testicular cancer: Cancer that develops in the testicles
  • Non-small cell lung cancer: A common type of lung cancer

This therapy is primarily intended for patients with advanced cancers that have not responded to other treatments or for whom no standard therapy is available[1].

Clinical Trial Details

CLDN6 CAR-T is currently being studied in a Phase I/IIa clinical trial[1]. This trial aims to:

  • Assess the safety and tolerability of CLDN6 CAR-T
  • Evaluate its effectiveness in treating advanced solid tumors
  • Determine the appropriate dosage
  • Study the therapy both alone and in combination with a vaccine called CLDN6 RNA-LPX

The trial is designed to include an initial dose escalation phase followed by an expansion phase with more patients[1].

Eligibility Criteria

To participate in the CLDN6 CAR-T clinical trial, patients must meet certain criteria[1]. Some key eligibility requirements include:

  • Having a CLDN6-positive tumor (confirmed by a specific test)
  • Being 18 years of age or older
  • Having adequate organ function (blood, liver, kidney)
  • Having a cancer that is metastatic or cannot be surgically removed
  • Having no available standard therapy likely to provide clinical benefit

There are also several exclusion criteria, such as having received prior CAR-T therapy (except CLDN6 CAR-T) or certain vaccinations[1].

Potential Benefits

While the effectiveness of CLDN6 CAR-T is still being studied, the therapy has the potential to offer several benefits[1]:

  • Targeted treatment of CLDN6-positive tumors
  • Possibility of treating various types of solid tumors
  • Option for patients who have exhausted other treatment options
  • Potential for long-lasting immune response against cancer cells

Safety Considerations

As with any experimental therapy, there are potential risks and side effects associated with CLDN6 CAR-T treatment[1]. The clinical trial is closely monitoring for:

  • Treatment-emergent adverse events (side effects that occur during or after treatment)
  • Serious or life-threatening side effects
  • Changes in levels of certain immune factors in the body

Patients considering this therapy should discuss potential risks and benefits thoroughly with their healthcare provider.

Aspect Details
Study Type Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts
Main Objective Assess safety and tolerability of CLDN6 CAR-T ± CLDN6 RNA-LPX
Target Population Adults with CLDN6-positive relapsed or refractory advanced solid tumors
Key Eligibility Criteria ≥50% of tumor cells expressing ≥2+ CLDN6 protein, adequate organ function, measurable disease
Primary Endpoints Treatment-emergent adverse events, dose-limiting toxicities
Secondary Endpoints Changes in immune factors, objective response rate, duration of response
Investigational Products CLDN6 CAR-T (BNT211), CLDN6 RNA-LPX
Administration Route Intravenous bolus use

FAQ

  • What is CLDN6 CAR-T therapy? CLDN6 CAR-T is an investigational cell therapy that uses a patient's own T cells, which are modified to target cancer cells expressing the CLDN6 protein. This therapy is being studied for its potential to treat advanced solid tumors.
  • Who is eligible for this clinical trial? Eligible participants are adults (18 years or older) with CLDN6-positive advanced solid tumors that are metastatic or unresectable. Patients must have no available standard therapy likely to provide clinical benefit or be unsuitable for such therapy.
  • What are the main objectives of this clinical trial? The primary objectives are to assess the safety and tolerability of CLDN6 CAR-T therapy, with or without an RNA-based vaccine. The trial also aims to evaluate the therapy's effectiveness in fighting tumors and to study changes in immune factors.
  • How is the CLDN6 protein identified in patients? CLDN6 protein expression is detected using a specialized immunohistochemistry (IHC) assay performed on tumor tissue samples in a central laboratory. Eligible patients must have at least 50% of tumor cells expressing CLDN6 at a level of 2+ or higher.
  • What are some potential side effects of this treatment? While specific side effects are not mentioned in the provided information, the trial closely monitors for treatment-emergent adverse events (TEAEs), including serious and potentially fatal events. The study also evaluates dose-limiting toxicities to ensure patient safety.

Ongoing Clinical Trials on Cldn6 Car-T

  • A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands Sweden

Glossary

  • CLDN6 CAR-T: A type of cell therapy where a patient's T cells (immune cells) are modified to express a Chimeric Antigen Receptor (CAR) that targets the CLDN6 protein found on some cancer cells.
  • RNA-LPX: A liposomally-formulated vaccine containing ribonucleic acid (RNA) that encodes for the CLDN6 protein. It's being studied in combination with CLDN6 CAR-T therapy.
  • Solid Tumors: Abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors may be benign or malignant (cancerous).
  • Immunohistochemistry (IHC): A laboratory method used to detect specific proteins in tissues, often used to diagnose certain types of cancers.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standardized way to measure if tumors are responding to treatment in cancer clinical trials.
  • Dose-Limiting Toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dose or level of that treatment.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Unresectable: A tumor that cannot be removed completely through surgery.
  • Lymphodepletion: A process of temporarily reducing the number of lymphocytes (a type of white blood cell) in the body, often done before certain cancer treatments.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-cldn6-car-t-and-cldn6-rna-lpx-in-patients-with-advanced-solid-tumors/